These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6206311)

  • 1. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia.
    Roden DM; Dawson AK; Duff HJ; Woosley RL; Smith RF
    J Cardiovasc Pharmacol; 1984; 6(4):588-95. PubMed ID: 6206311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog.
    Dawson AK; Roden DM; Duff HJ; Woosley RL; Smith RF
    Am J Cardiol; 1984 Sep; 54(6):654-8. PubMed ID: 6475789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic activity of the O-demethyl metabolite of encainide.
    Roden DM; Duff HJ; Altenbern D; Woosley RL
    J Pharmacol Exp Ther; 1982 Jun; 221(3):552-7. PubMed ID: 6806461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiologic actions of O-demethyl encainide: an active metabolite.
    Duff HJ; Dawson AK; Roden DM; Oates JA; Smith RF; Woosley RL
    Circulation; 1983 Aug; 68(2):385-91. PubMed ID: 6861313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.
    Davy JM; Dorian P; Kantelip JP; Harrison DC; Kates RE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):907-11. PubMed ID: 3086540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs.
    Kerr MJ; Allen JD; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1985; 7(3):449-57. PubMed ID: 2410673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiological effects of encainide and its metabolites in normal canine Purkinje fibers and Purkinje fibers surviving infarction.
    Kinnaird AA; Man RY
    Can J Physiol Pharmacol; 1989 Jul; 67(7):751-6. PubMed ID: 2504469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic effects of encainide following acute coronary occlusion in dogs.
    Ro JH; Gillon J; Kupersmith J
    J Cardiovasc Pharmacol; 1981; 3(3):532-40. PubMed ID: 6168834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic modeling of antiarrhythmic drug effects--application to 3-methoxy-O-demethyl encainide.
    Dorian P; Davy JM; Kates RE
    J Cardiovasc Pharmacol; 1986; 8(6):1217-22. PubMed ID: 2434749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and electrophysiologic effects of encainide in patients with bundle branch block.
    Schwartz AB; Shapiro WA; Suave MJ; Shen E; Bhandari A; Morady F; Scheinman M
    Can J Cardiol; 1987 Mar; 3(2):75-82. PubMed ID: 3105850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia.
    Naccarelli GV; Jackman WM; Akhtar M; Rinkenberger RL; Friday KJ; Dougherty AH; Tchou P; Yeung-Lai-Wah JA
    Am J Cardiol; 1988 Dec; 62(19):31L-36L. PubMed ID: 3144165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encainide: a new antiarrhythmic agent.
    Wehmeyer AE; Thomas RL
    Drug Intell Clin Pharm; 1986 Jan; 20(1):9-13. PubMed ID: 3080301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide.
    Bajaj AK; Woosley RL; Roden DM
    Circulation; 1989 Oct; 80(4):994-1002. PubMed ID: 2551538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of encainide and its metabolites on energy requirements for defibrillation.
    Fain ES; Dorian P; Davy JM; Kates RE; Winkle RA
    Circulation; 1986 Jun; 73(6):1334-41. PubMed ID: 3084128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encainide.
    Antonaccio MJ; Gomoll AW; Byrne JE
    Cardiovasc Drugs Ther; 1989 Oct; 3(5):691-710. PubMed ID: 2518680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia.
    Chimienti M; Li Bergolis M; Moizi M; Salerno JA
    J Am Coll Cardiol; 1989 Oct; 14(4):992-8. PubMed ID: 2507613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.